March 22, 2024
Amsterdam, the Netherlands - Royal Philips (http://www.philips.com/newscenter)
(NYSE: PHG, AEX: PHIA), today announced it has convened the Annual General
Meeting of Shareholders (AGM) 2024 and published the agenda with explanatory
notes.
As previously announced, the agenda includes:

  * Proposals to re-appoint Chairman Feike Sijbesma (Dutch, 1959) and Peter
    Löscher (Austrian, 1957) as members of the Supervisory Board, with effect
    from May 7, 2024.
  * Proposal to appoint Charlotte Hanneman (Dutch, 1978) as member of the Board
    of Management, fulfilling the role of Chief Financial Officer, with effect
    from October 1, 2024.
  * Proposal to appoint Benoît Ribadeau-Dumas (French, 1972) as new member of
    the Supervisory Board, with effect from May 7, 2024.

The agenda furthermore includes:

  * Proposals to adopt an amended Remuneration Policy for the Board of
    Management and an amended Remuneration Policy for the Supervisory Board.
  * A number of recurring items, such as the 2023 Remuneration Report as
    included in the Annual Report 2023 (advisory vote), and the proposals to
    adopt the company's financial statements and dividend.

The AGM will be held at the Hotel Hilton Amsterdam, Apollolaan 138, Amsterdam on
Tuesday, May 7, 2024, beginning at 14:00 CET.
The complete agenda with explanatory notes, the Annual Report 2023 (which was
published on February 20, 2024), the binding nominations, the proposed
Remuneration Policies and other information relevant for the AGM have been
published here (http://www.philips.com/agm).
For further information, please contact:
Elco van Groningen
Philips External Relations
Tel.: +31 6 8103 9584
E-mail: elco.van.groningen@philips.com (mailto:elco.van.groningen@philips.com)
Dorin Danu
Philips Investor Relations
Tel: +31 20 5977055
E-mail: dorin.danu@philips.com (mailto:dorin.danu@philips.com)
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company
focused on improving people's health and well-being through meaningful
innovation. Philips' patient- and people-centric innovation leverages advanced
technology and deep clinical and consumer insights to deliver personal health
solutions for consumers and professional health solutions for healthcare
providers and their patients in the hospital and the home. Headquartered in the
Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-
guided therapy, monitoring, and enterprise informatics, as well as in personal
health. Philips generated 2023 sales of EUR 18.2 billion and employs
approximately 69,700 employees with sales and services in more than 100
countries. News about Philips can be found at www.philips.com/newscenter
(http://www.philips.com/newscenter).
Forward-looking statements
This release contains certain forward-looking statements with respect to the
financial condition, results of operations and business of Philips and certain
of the plans and objectives of Philips with respect to these items. Examples of
forward-looking statements include statements made about the strategy, estimates
of sales growth, future EBITA, future developments in Philips' organic business
and the completion of acquisitions and divestments. By their nature, these
statements involve risk and uncertainty because they relate to future events and
circumstances and there are many factors that could cause actual results and
developments to differ materially from those expressed or implied by these
statements.
Â